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The Impact of Obstructive versus Restrictive Lung Disease on Mortality in
Patients Undergoing Transcatheter Aortic Valve Replacement
Ricardo Escarcega Alarcon, Rebecca Torguson, Joelle Salmon, Edward Koifman,
Sarkis Kiramijyan, Marco Magalhaes, Arpi Tavil-Shatelyan, Youstina Daoud,
Nevin Baker, Michael Lipinski, Petros Okubagzi, Lowell Satler, Augusto Pichard,
Ron Waksman
MedStar Washington Hospital Center, MedStar Heart Institute, Washington, DC
BACKGROUND Pulmonary function tests (PFTs) to estimate force vital capacity (FVC)
and forced expiratory volume in 1 sec (FEV1) has increasingly being used in patients
evaluated for transcatheter aortic valve replacement (TAVR). The impact of
obstructive versus restrictive lung disease on mortality remains unclear.
Hypothesis: We sought to identify differences in survival in patients with 2 distinct
pulmonary function patterns (obstruction vs restriction).
METHODS We retrospectively analyzed all patients with abnormal FEV1 (lower
than 80% of predicted) detected on the PFTs prior to TAVR from May 2011 to
March 2014. Patients were divided into patients with obstructive pattern (FEV1/
FCV<70% of predicted) and patients with restrictive pattern (FEV1/FVC>70% of
predicted). Cox-proportional hazards regression was used to explore the impact of
FEV1 on mortality.
RESULTS A total of 82 patients were included in this analysis. 42% (n¼35) had
obstructive pattern and 58% (n¼47) had restrictive pattern. FEV1 values were similar
between both groups (45  19 vs 42  26, p¼0.72). Both groups had similar rates of in-
hospital death, 30-day and 1-year mortality (ﬁgure). FEV1 was not a correlate for 1
year mortality (HR 0.99, 95%CI 0.97-1.01, p¼0.41).
CONCLUSION In our population, patients with pulmonary obstructive and restrictive
patters had similar rates of mortality. Moreover, FEV1 value was not a correlate for
1 year mortality. In patients undergoing TAVR, the pattern on PFTs or FEV1 values is
not helpful for the assessment of eligibility patients who are candidates for TAVR.CRT-812
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Treatment of Bio-Prosthetic Valve Deterioration Using The Valve-in-Valve
Technique
Pablo Codner, Abid Assali, Hana Vaknin-Assa, Katia Orvin, Gabriel Greenberg,
Yaron Shapira, Alexander Sagie, Ran Kornowski
Rabin Medical Center, Petah Tikwa, Israel
BACKGROUND Trans-catheter heart valve implantation is a therapeutic option for the
treatment of patients with bioprosthetic valve failure. We describe our experience
using this technique in the treatment of degenerated mitral, aortic and tricuspid
bioprosthetic-valves.
METHODS 33 patients underwent a valve-in-valve procedure, with the implantation
of 34 percutaneous implantable valves. Both, the Edwards-Sapien and the CoreValve
devices were used. Outcomes were evaluated using the Valve Academic Research
Consortium 2 criteria.
RESULTS Valve-in-Valve in the aortic position: mean age of patients was 81.4  5.9
years. NYHA III/IV before the procedure was present in 95.6% of patients. Mean STS
score was 9.0  5.4. Mean aortic valve gradients was 42.2  6.1 mmHg. The CoreValve
and the Edwards-Sapien valve devices were used in 91.3% and 8.7% of patients,respectively. The CoreValve device was implanted via the trans-axillar route in 3
cases and via trans-femoral route in 18 cases. The trans-apical route was used in both
Edwards-Sapien implantations. Procedural success was achieved in 100% of cases.
One month and one year survival rates were 100% and 90%; respectively. At one
month follow up, 95.7% of patients were in NYHA I/II.
Valve-in-Valve in the mitral position: mean age of patients was 73.6  15 years.
NYHA III/IV before the procedure was present in 100% of patients. Mean STS score
was 7.7  4.1. Mode of failure was severe mitral regurgitation in 100% of cases. All the
procedures were performed with the Edwards-Sapien device via the trans-apical
route. Procedural success was achieved in 100% of cases. One month and one year
survival rates were 90% and 80%; respectively. At one month follow up, 100% of
patients were in NYHA I/II.
Valve-in-Valve in the tricuspid position, was performed in a 78 year-old female
patient. The patient was in NYHA IV secondary to severe tricuspid stenosis due to the
deterioration of a bioprosthetic Handcock 31mm valve. An Edwards-Sapien 29mm
valve was implanted via the trans-femoral vein route. The procedure went un-
eventful. At one month follow up the patient was in NYHA-FC II.
CONCLUSION In our experience, the Valve-in-Valve procedure for the treatment of
failed mitral, aortic and tricuspid bio-prosthetic valves, using multiple access tech-
niques and available devices, led to signiﬁcant symptomatic improvement, low peri-
procedural morbidity and low mortality rates.
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Presence Of Diabetes Is Associated With Aortic Valve Disorder
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BACKGROUND Diabetes is a risk factor for cardiovascular disease. The goal of this
study was to evaluate any association between aortic valve disease and diabetes
using a very large database.
METHOD The Nationwide Inpatient Sample (NIS) database was utilized to perform
statistical analysis to evaluate prevalence of aortic valve disease (ICD-9 code: 424.1 in
diabetes vs non diabetes patient using two samples yeas 10 years apart in 1997 and
2007 in the United States.
RESULTS A total of 1,410,132 patients with a diagnosis of diabetes were identiﬁed from
year 2007 from a population of 8,043,415 inpatients admissions. The prevalence of
aortic valve disease was 1.9 % in DM patients vs 1.1 in pt without DM, p<0.0001.
Obesity increased over the years. In year 1997, a total of 912,466 patients were iden-
tiﬁed with DM from a total population of 7,148,420 inpatients admission. Prevalence of
aortic valve disease was 1.7% in DM patients vs, 1% in patients without DM, p<0.0001.
CONCLUSION Using a very large data base, we ﬁnd signiﬁcantly higher prevalence of
aortic valve disease in DM patients. This suggests that DM has a negative effect on the
aortic valve apparatus.
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A Meta-analysis Of Clinical Outcomes Between Edwards Valve Versus Corevalve
After Transcatheter Aortic Valve Replacement
Satish Chandraprakasam, Jitendra Pandya, Arun Kanmantha Reddy,
Venkata Mahesh Babu Alla
Creighton University, Omaha, NE
BACKGROUND Transcatheter aortic valve replacement (TAVR) has been approved by
US FDA for high surgical risk and inoperable patients with severe aortic stenosis.
However, there is no single large study comparing the performance of valves with
respect to mortality or stroke.
OBJECTIVE To compare the 30-day mortality and stroke outcomes in TAVR patients
treated with balloon expandable valve (BEV, Edwards Lifesciences Corporation,
Irvine, Ca) and self-expanding valve (SEV, Medtronic CV, Luxembourg S.a.r.l.).
METHODS We performed an electronic search for studies published between 2009
and 2014 reporting clinical outcomes for BEV and SEV. Pooled odd’s ratio with 95%
conﬁdence intervals was calculated using Mantel Haenszel random effects model.
RESULTS A total of 165 studies were initially selected of which 10 studies were
included in the ﬁnal analysis, yielding a total of 5204 patients (2779 with Edwards
Valve and 2425 with CoreValve). Pooled estimate of 30-day mortality was 9.4% (493/
5204) and of stroke was 1.3% (71/5204). There was no difference in the 30-day mor-
tality between the valves (OR 1.03, 95% CI 0.76 to 1.39). There was no statistically
signiﬁcant difference in stroke risk (OR 1.75, 95% CI 0.96 to 3.21). Figure 1
CONCLUSION Post-operative mortality and stroke risk appear to be similar with both
valves. Large randomized controlled trials assessing clinical outcomes are warranted
as these analyses may be confounded by heterogeneity in study population, baseline
risk characteristics and TAVR approaches.
